Novel "ruthenium cyclopentadienyl" - peptide conjugate complexes against human FGFR(+) breast cancer
- 13 May 2020
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 49 (18), 5974-5987
- https://doi.org/10.1039/d0dt00955e
Abstract
In this work we explored the possibility of improving the selectivity of a cytotoxic Ru complex [RuCp(PPh3)(2,2'-bipy)][CF3SO3] (where Cp = eta(5)-cyclopentadienyl) TM34 towards FGFR(+) breast cancer cells. Molecular dynamics (MD) simulations of TM34 in a phosphatidylcholine membrane model pinpointed the cyclopentadienyl group as a favorable derivatization position for the peptide conjugation approach. Three new Ru(II) complexes presenting a functionalized eta(5)-cyclopentadienyl were synthesized, namely [Ru(eta(5)-C5H4COOH)(2,2'-bipy)(PPh3][CF3SO3] (TM281) and its precursors, [Ru(eta(5)-C5H4COOCH2CH3)(eta(2)-2,2'-bipy)(PPh3)][CF3SO3] (3) and [Ru(eta(5)-C5H4COOCH2CH3)(PPh3)(2)Cl] (2). Complex TM281 was prepared by the hydrolysis of the ethyl ester group appended to the eta(5)-cyclopentadienyl ligand of complex 3 with K2CO3 in water/acetonitrile, followed by mild protonation using an ion exchange resin. The newly synthesized complexes were fully characterized by NMR, FTIR and UV-vis spectroscopic techniques. Also, electrochemical studies were carried out by means of cyclic voltammetry in order to evaluate the stability of the compounds. Single crystal X-ray diffraction studies were carried out for compounds 3 and TM281 which crystallized in the monoclinic system, space group P21/n. The unprecedented synthesis and characterization of three half-sandwich ruthenium(II)-cyclopentadienyl peptide conjugates and their preliminary biological evaluation against human FGFR(+) and FGFR(-) breast cancer cells are also reported.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (UIDB/00100/2020, UID/Multi/04349/2019, CEECIND/00630/2017, SFRH/BD/135915/2018, CEECIND/02300/2017, UID/MULTI/04046/2019, PTDC/QUI-NUC/30147/2017, LISBOA-01-0145-FEDER-022125)
This publication has 62 references indexed in Scilit:
- Future directions for peptide therapeutics developmentDrug Discovery Today, 2013
- GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkitBioinformatics, 2013
- Studies of the Antiproliferative Activity of Ruthenium (II) Cyclopentadienyl-Derived Complexes with Nitrogen Coordinated LigandsBioinorganic Chemistry and Applications, 2010
- Structure validation in chemical crystallographyActa Crystallographica Section D-Structural Biology, 2009
- Studies on anticancer activities of antimicrobial peptidesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2008
- A short history of SHELXActa Crystallographica Section A Foundations of Crystallography, 2007
- Photophysical Properties of Ruthenium Bipyridine (4-Carboxylic acid-4‘-methyl-2,2‘-bipyridine) Complexes and Their Acid−Base ChemistryThe Journal of Physical Chemistry B, 2007
- Canonical sampling through velocity rescalingThe Journal of Chemical Physics, 2007
- Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibitionChemico-Biological Interactions, 1995
- A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP modelThe Journal of Physical Chemistry, 1993